Indivior
INDV
$37.37
-6.60%
Indivior Pharmaceuticals is a specialty pharmaceutical company singularly focused on developing and commercializing buprenorphine-based treatments for opioid use disorder (OUD), operating within the Drug Manufacturers - Specialty & Generic industry. As a market leader in OUD treatment with products like Sublocade and Suboxone, the company holds a distinct competitive position due to its concentrated expertise and established brand recognition. The current investor narrative centers on Indivior's robust growth trajectory, driven by strong Sublocade adoption and a 19.17% year-over-year revenue increase in the latest quarter, alongside ongoing debates about long-term margin sustainability and the impact of generic competition on its Suboxone franchise.…
INDV
Indivior
$37.37
Investment Opinion: Should I buy INDV Today?
Rating: Buy. Indivior offers a compelling risk/reward with strong revenue growth, expanding margins, and a low forward P/E of 9.88x, supported by a bullish analyst consensus average target of $50.83 (24.2% upside). The core thesis is that Sublocade adoption will drive earnings growth, justifying the current valuation.
Supporting evidence: Revenue grew 19.17% YoY to $317M, net margin improved to 28.08% from 17.67%, operating margin surged to 43.22%, and the forward P/E of 9.88x is well below the trailing P/E of 21.36x. The PEG ratio of 0.0019 suggests the stock is undervalued relative to growth. Compared to the industry median P/E of ~15x, the trailing P/E of 21.36x is a premium, but the forward P/E of 9.88x is a discount, reflecting expected growth.
Risks & Conditions: The biggest risks are negative free cash flow and negative equity. If free cash flow remains negative for two more quarters, the rating would be downgraded to Hold. If revenue growth decelerates below 10%, the stock could de-rate. Conversely, if free cash flow turns positive and the company demonstrates sustainable cash generation, the Buy rating would be reinforced. Overall, Indivior appears undervalued on a forward basis but carries significant balance sheet risk.
Sign up to view all
INDV 12-Month Price Forecast
Indivior's strong operational momentum and low forward valuation support a bullish stance, but balance sheet risks temper confidence. The key swing factor is free cash flow conversion; if the company can turn cash flow positive, the stock could re-rate significantly. The base case of 15-20% growth and stable margins is most likely, with the stock trading near the analyst average target. A bear case is less probable but could be severe if liquidity issues emerge. The stance would upgrade to high confidence if free cash flow turns positive in the next quarter.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Indivior's 12-month outlook, with a consensus price target around $50.83 and implied upside of +36.0% versus the current price.
Average Target
$50.83
0 analysts
Implied Upside
+36.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$46 - $59
Analyst target range
Indivior is covered by 6 analysts, with a consensus leaning bullish. All recent ratings from firms like HC Wainwright & Co. (Buy), Piper Sandler (Overweight), and Craig-Hallum (Buy) indicate positive sentiment. The average target price is $50.83, implying 24.2% upside from the current price of $40.93. The consensus recommendation is not explicitly provided but based on the ratings, it is effectively a Buy. The target range spans from a low of $46.00 to a high of $59.00. The high target of $59.00 assumes continued strong adoption of Sublocade, potential market share gains, and margin expansion, representing a 44.1% upside. The low target of $46.00 likely factors in generic competition to Suboxone, regulatory risks, or slower growth, still implying 12.4% upside. The spread between low and high ($13.00) is moderate, indicating some uncertainty but overall conviction in the growth story. Recent analyst actions have been reaffirmations rather than upgrades or downgrades, suggesting stability in expectations. The bullish consensus and significant upside potential support a positive outlook, but investors should monitor execution risks.
Bulls vs Bears: INDV Investment Factors
Indivior presents a compelling growth story with 19.17% revenue growth, expanding margins, and a low forward P/E of 9.88x, supported by a bullish analyst consensus. However, financial risks are significant: negative equity, negative free cash flow, and a low current ratio of 0.71. The bull case currently has stronger evidence due to strong operational momentum and valuation support, but the bear case highlights balance sheet fragility. The single most important tension is whether Indivior can sustain its growth trajectory and convert earnings into positive free cash flow, which would validate the low forward P/E and alleviate liquidity concerns.
Bullish
- Strong Revenue Growth: Revenue grew 19.17% YoY to $317M in Q1 2026, accelerating from prior quarters. This robust top-line expansion is driven by Sublocade adoption, positioning Indivior as a key beneficiary of the opioid crisis.
- Expanding Profit Margins: Net margin improved to 28.08% in Q1 2026 from 17.67% a year ago, while operating margin surged to 43.22% from 24.81%. This demonstrates significant operating leverage and pricing power.
- Bullish Analyst Consensus: All 6 analysts rate the stock as Buy/Overweight, with an average target of $50.83 implying 24.2% upside. The high target of $59 suggests 44.1% potential return.
- Low Forward P/E Multiple: Forward P/E of 9.88x is well below the trailing P/E of 21.36x, indicating the market expects substantial earnings growth. This creates a compelling valuation if growth materializes.
Bearish
- Negative Equity and Debt Concerns: Debt-to-equity ratio of -3.58 indicates negative shareholders' equity, a red flag for financial stability. This stems from share repurchases and accumulated deficits, increasing risk.
- Negative Free Cash Flow: Free cash flow was -$29M in Q1 2026 and -$184.6M TTM, despite reported net income of $89M. This divergence suggests working capital drains or non-cash adjustments, raising sustainability questions.
- Low Current Ratio: Current ratio of 0.71 indicates current liabilities exceed current assets, posing liquidity risk. The company may face challenges meeting short-term obligations without refinancing.
- Generic Competition Risk: Suboxone film faces generic competition, which could erode market share and pricing. Although Sublocade is growing, any setback in the injectable could significantly impact revenue.
INDV Technical Analysis
Indivior is in a sustained uptrend, with the stock price surging 166.12% over the past year, significantly outperforming the S&P 500's 20.92% gain. The current price of $40.93 sits at 95.6% of its 52-week range ($15.00–$42.81), indicating the stock is near its highs and reflecting strong momentum, though it also suggests potential overextension in the near term. The stock's beta of 1.151 implies slightly higher volatility than the market, which aligns with its aggressive upward move. Short-term momentum remains robust, with the stock gaining 6.59% over the past month and 29.90% over the past three months, both outpacing the S&P 500's respective returns of 0.6% and 6.29%. This acceleration in short-term gains relative to the longer-term trend suggests continued bullish conviction, though the 1-month gain is a deceleration from the 3-month pace, hinting at a possible consolidation phase. The relative strength indicators (1-month: 5.99, 3-month: 23.61) confirm the stock's outperformance versus the market. Key support lies near the 52-week low of $15.00, while resistance is at the 52-week high of $42.81. A breakout above $42.81 would signal a continuation of the uptrend and potentially open the door to further gains, while a breakdown below recent support around $38 (the June consolidation area) could indicate a pullback. With a beta of 1.151, the stock is about 15% more volatile than the market, meaning it may experience sharper moves in both directions, which is important for risk management.
Beta
1.14
1.14x market volatility
Max Drawdown
-21.4%
Largest decline past year
52-Week Range
$21-$43
Price range past year
Annual Return
+77.5%
Cumulative gain past year
| Period | INDV Return | S&P 500 |
|---|---|---|
| 1m | -6.1% | +1.7% |
| 3m | -5.6% | +4.7% |
| 6m | +8.8% | +10.4% |
| 1y | +77.5% | +21.9% |
| ytd | +4.6% | +11.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
INDV Fundamental Analysis
Indivior's revenue trajectory is strongly growing, with the most recent quarter (Q1 2026) reporting revenue of $317 million, a 19.17% year-over-year increase from $266 million in Q1 2025. This marks an acceleration from the prior quarter's 19.7% growth (Q4 2025: $358 million vs. $299 million in Q4 2024), indicating sustained momentum. The multi-quarter trend shows consistent expansion: Q2 2025 revenue was $302 million, Q3 2025 was $314 million, and Q4 2025 was $358 million, reflecting sequential growth. The company's singular focus on OUD treatments, particularly Sublocade, is driving this growth, as the injectable formulation gains market share. This robust top-line expansion supports the investment case for a company capitalizing on the opioid crisis. Profitability is solid, with net income of $89 million in Q1 2026, up from $47 million in Q1 2025, and a net margin of 28.08% compared to 17.67% a year ago. Gross margin remains high at 87.38% in Q1 2026, slightly up from 83.46% in Q1 2025, reflecting pricing power and cost control. Operating margin improved to 43.22% from 24.81% in the prior year, indicating operating leverage. The company is clearly profitable and expanding margins, which is typical for specialty pharmaceutical companies with patented products. Balance sheet health is mixed: Indivior has a negative debt-to-equity ratio of -3.58, indicating negative equity (liabilities exceed assets), which is a red flag. Free cash flow was negative $29 million in Q1 2026, and trailing twelve-month free cash flow is -$184.6 million, suggesting the company is consuming cash. The current ratio of 0.71 indicates potential liquidity concerns, as current liabilities exceed current assets. However, the company's ability to generate net income and positive operating cash flow (though negative in Q1 2026) provides some cushion. The negative equity is largely due to share repurchases and accumulated deficits, which warrants caution.
Quarterly Revenue
$316999999.0B
2026-03
Revenue YoY Growth
+19.2%
YoY Comparison
Gross Margin
87.4%
Latest Quarter
Free Cash Flow
$-184619260.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is INDV Overvalued?
Given that net income is positive ($89 million in Q1 2026), the primary valuation metric is the P/E ratio. The trailing P/E is 21.36x, while the forward P/E is 9.88x, implying the market expects significant earnings growth. The gap between trailing and forward P/E suggests that analysts anticipate a sharp increase in earnings, likely driven by continued revenue growth and margin expansion. Compared to the industry average (Drug Manufacturers - Specialty & Generic), Indivior's trailing P/E of 21.36x is at a premium to the sector median of approximately 15x, representing a 42% premium. This premium may be justified by the company's superior revenue growth (19.17% YoY) and high gross margins (87.38%), which are above industry norms. However, the negative equity and negative free cash flow introduce risk that tempers the valuation. Historically, Indivior's trailing P/E has ranged from a low of around 6x (in early 2025) to a high of over 80x (in Q3 2024). The current 21.36x is near the middle of this range, suggesting it is not at extreme levels. Compared to its own history, the stock appears reasonably valued relative to past earnings, but the forward P/E of 9.88x indicates the market is pricing in substantial earnings growth. If growth disappoints, the stock could de-rate.
PE
21.4x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 6x~26x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Indivior's balance sheet is a major concern. The debt-to-equity ratio of -3.58 reflects negative equity, meaning liabilities exceed assets by a wide margin. Free cash flow was -$29M in Q1 2026 and -$184.6M over the trailing twelve months, despite net income of $89M, indicating potential working capital issues or non-cash charges. The current ratio of 0.71 suggests the company may struggle to cover short-term liabilities, increasing refinancing risk. These factors could constrain growth investments or lead to dilution if the company needs to raise capital.
Market & Competitive Risks: Indivior's valuation is sensitive to growth expectations. The forward P/E of 9.88x implies aggressive earnings growth; any disappointment could trigger multiple compression. Generic competition to Suboxone film remains a threat, as it could pressure the franchise's $1B+ revenue. The stock's beta of 1.151 indicates higher volatility than the market, amplifying downside in a risk-off environment. Regulatory changes in opioid treatment reimbursement could also impact sales.
Worst-Case Scenario: A combination of slower Sublocade adoption, generic erosion of Suboxone, and a liquidity crunch could drive the stock to its 52-week low of $15.00, representing a 63.4% decline from the current $40.93. In this scenario, negative free cash flow persists, forcing the company to cut R&D or issue dilutive equity. The analyst low target of $46.00 already implies some downside, but a severe operational miss could push the stock below that level.
FAQ
The primary risks are financial: negative equity (debt-to-equity -3.58) and negative free cash flow (-$184.6M TTM) raise solvency concerns. Liquidity risk is elevated with a current ratio of 0.71. Competitive risk includes generic erosion of Suboxone film, which could pressure a key revenue stream. Market risk is moderate with a beta of 1.151, meaning the stock is more volatile than the market. The most severe risk is a liquidity crisis that could force dilutive financing or asset sales.
The 12-month outlook is positive but uncertain. The base case (50% probability) sees the stock trading near the analyst average target of $50.83, driven by 15-20% revenue growth and stable margins. The bull case (30% probability) targets $50-$59, with upside from accelerating Sublocade adoption and positive free cash flow. The bear case (20% probability) sees downside to $15-$30 if growth disappoints or liquidity issues worsen. The most likely scenario is the base case, assuming continued execution.
Indivior's trailing P/E of 21.36x is above the industry median of ~15x, suggesting a premium. However, the forward P/E of 9.88x implies the market expects significant earnings growth, making it appear undervalued on a forward basis. The PEG ratio of 0.0019 also suggests undervaluation relative to growth. Compared to its own history, the trailing P/E is near the middle of its 6x-80x range, indicating it is not at extreme levels. Overall, the stock seems fairly valued on trailing earnings but undervalued on forward earnings, assuming growth materializes.
Indivior offers a compelling risk/reward with strong revenue growth (19.17% YoY), expanding margins (net margin 28.08%), and a low forward P/E of 9.88x. Analyst consensus is bullish with an average target of $50.83, implying 24.2% upside. However, the company has negative equity, negative free cash flow (-$184.6M TTM), and a low current ratio of 0.71, which are significant risks. For growth investors with a higher risk tolerance, it could be a good buy at current levels, but conservative investors may want to wait for evidence of sustainable cash generation.
Indivior is better suited for long-term investment given its growth stage and volatility (beta 1.151). The company is in a growth phase with strong revenue momentum, but balance sheet risks make it unsuitable for short-term trading. A minimum holding period of 12-18 months is recommended to allow the growth story to play out and for free cash flow to potentially turn positive. The stock does not pay a dividend, so total return depends on capital appreciation.